This is the authors' abstract. We don't add key points for this paper.
Objective: To determine whether sepimostat mesilate inhibits activation of the complement pathways, and to evaluate the effectiveness of sepimostat mesilate on the development of glomerulonephritis in NZB/W F1 mice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: